Kerstin Valinder

About Immedica Pharma Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Welcome to the Immedica social media channels The Immedica social channels are set up to share news, updates, and company happenings with all visitors. Please note that postings by other visitors do not necessarily reflect the opinion of Immedica or confirm their accuracy. Immedica will routinely monitor comments and Immedica reserves the right to remove any posts that do not comply with our guidelines and to block anyone who violates them repeatedly. Examples of reasons for having a comment removed from a post on our social media might be: - References a side effect or complaint - Reporting of an adverse event, side effect or reaction from an Immedica product (that information should be reported directly to Immedica Drug Safety or to your physician.) - A reference to a product or treatment We work in a highly regulated industry that does not allow us to engage with the public in discussions about products – ours or other companies – or treatment options. We never provide healthcare advice - your doctor or health care provider is the person to ask. If you have a product enquiry, please email the Immedica medical department. - Abusive language We welcome your feedback, provided that you share your view in a way that is respectful to our community, meaning not inappropriate, off-topic, harassing, spamming in nature, or promoting/soliciting third-party sites, initiatives, or products Social media platforms may occasionally be unavailable, and we accept no responsibility for lack of service due to social media platform downtime.

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma’s two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical Phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on the Nasdaq First North Growth Market (ticker "PROMO"​).

Gedea Biotech developes pHyph to treat and prevent recurrence of bacterial vaginosis. Bacterial vaginosis (BV) is a very common condition with a prevalence of 10-30% for women of childbearing age. The symptoms can very disturbing and include an often profuse thin, white, “fishy” smelling vaginal discharge, in the absence of itching. Standard treatment consists of antimicrobials, but recurrence rate is15–30 % within 3 months. pHyph will treat the infection and prevent recurrence without the use of antmicrobials. Antimicrobial resistance is one of the World Health Organisation’s top ten threats to global health in 2021 and research into novel non-antimicrobial based treatments is timely.

Bioservo is a technology and development company that combines medical science with modern robotics. The company has a leading global position within soft exoskeleton technology, wearable non-invasive products, for people in need of extra power to support the bodys endurance and performance, or for people with reduced muscular strength. After many years of research and development, Bioservo now focus on the commercialization of its products and patented technologies. The developed gloves are well suited for both rehabilitation within health and medical care and preventively for professionals in the industry. The company has signed strategic cooperation agreements with several multinational companies within e.g. the automobile, aircraft as well as the construction and infrastructure industry. The technology was invented in 2006 through a collaboration between researchers at the Royal Institute of Technology and doctors at Karolinska University hospital in Stockholm. Bioservo AB is a Swedish company with headquarters and operations in Kista, north of Stockholm. For more information, please visit www.bioservo.com

About Immedica Pharma Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Welcome to the Immedica social media channels The Immedica social channels are set up to share news, updates, and company happenings with all visitors. Please note that postings by other visitors do not necessarily reflect the opinion of Immedica or confirm their accuracy. Immedica will routinely monitor comments and Immedica reserves the right to remove any posts that do not comply with our guidelines and to block anyone who violates them repeatedly. Examples of reasons for having a comment removed from a post on our social media might be: - References a side effect or complaint - Reporting of an adverse event, side effect or reaction from an Immedica product (that information should be reported directly to Immedica Drug Safety or to your physician.) - A reference to a product or treatment We work in a highly regulated industry that does not allow us to engage with the public in discussions about products – ours or other companies – or treatment options. We never provide healthcare advice - your doctor or health care provider is the person to ask. If you have a product enquiry, please email the Immedica medical department. - Abusive language We welcome your feedback, provided that you share your view in a way that is respectful to our community, meaning not inappropriate, off-topic, harassing, spamming in nature, or promoting/soliciting third-party sites, initiatives, or products Social media platforms may occasionally be unavailable, and we accept no responsibility for lack of service due to social media platform downtime.

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma’s two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical Phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on the Nasdaq First North Growth Market (ticker "PROMO"​).

Gedea Biotech developes pHyph to treat and prevent recurrence of bacterial vaginosis. Bacterial vaginosis (BV) is a very common condition with a prevalence of 10-30% for women of childbearing age. The symptoms can very disturbing and include an often profuse thin, white, “fishy” smelling vaginal discharge, in the absence of itching. Standard treatment consists of antimicrobials, but recurrence rate is15–30 % within 3 months. pHyph will treat the infection and prevent recurrence without the use of antmicrobials. Antimicrobial resistance is one of the World Health Organisation’s top ten threats to global health in 2021 and research into novel non-antimicrobial based treatments is timely.

KLIFO is a drug development consultancy and full-service Clinical Trial Supply with significant experience in partnering with pharmaceutical and biotech companies. We enable our partners to maximise opportunity, mitigate risks, drive innovation and achieve efficient project advancement. We offer end to end solutions across all drug development areas, including strategic project management, regulatory affairs, clinical development, clinical trial supply, quality assurance (QA), Chemistry Manufacturing and Controls (CMC) development, non-clinical development and pharmacovigilance in relation to the development of pharmaceutical products. We provide strategic advice as well as operational support in all these areas, and we partner with clients on portfolio strategies, project development strategies and project execution. KLIFO has offices in Denmark and Sweden and employs more than 130 highly skilled experts.